Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2 inhibitors: meta-analysis of controlled clinical trials

Daniel R. Morales (Lead / Corresponding author), Brian J. Lipworth, Bruce Guthrie, Cathy Jackson, Peter T. Donnan, Virginia H. Santiago

    Research output: Contribution to journalArticlepeer-review

    42 Citations (Scopus)

    Abstract

    Nonsteroidal anti-inflammatory drugs (NSAIDs) cause bronchospasm in susceptible patients with asthma, often termed aspirin-exacerbated respiratory disease (AERD), with the risk being greatest after acute exposure. Selective NSAIDs that preferentially inhibit COX-2 might be safer.
    Original languageEnglish
    Pages (from-to)40-45.e10
    Number of pages16
    JournalJournal of Allergy and Clinical Immunology
    Volume134
    Issue number1
    Early online date31 Dec 2013
    DOIs
    Publication statusPublished - Jul 2014

    Keywords

    • Asthma
    • aspirin-exacerbated respiratory disease
    • aspirin-induced asthma
    • aspirin-sensitive asthma
    • nonsteriodal anti-inflammatory agents
    • COX-2 inhibitors
    • Systematic review
    • Meta-analysis
    • PHARMACOEPIDEMIOLOGY

    Fingerprint Dive into the research topics of 'Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2 inhibitors: meta-analysis of controlled clinical trials'. Together they form a unique fingerprint.

    Cite this